Israeli PolyPid signs $320 million deal to sell drug preventing surgical infections in US, Canada
--------------------------------------------------------------------
Source: The Jerusalem Post
Published: 2026-07-22 00:04 UTC+10:00
Section: General
Factuality Score: 100
Opinion Category: Neutral
Topics: Health, Technology & AI, Drugs, Business & Economy, Technology
--------------------------------------------------------------------
Snippet:
PolyPid, an Israeli biotech company, said on Tuesday it had agreed a deal with Azurity Pharmaceuticals to commercialize a drug aimed at preventing surgical site infections in the US and Canada, under which it could receive more than $320 million.
--------------------------------------------------------------------